Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 1;138(9):974-980.
doi: 10.1001/jamaophthalmol.2020.2974.

Application of the Sight Outcomes Research Collaborative Ophthalmology Data Repository for Triaging Patients With Glaucoma and Clinic Appointments During Pandemics Such as COVID-19

Affiliations

Application of the Sight Outcomes Research Collaborative Ophthalmology Data Repository for Triaging Patients With Glaucoma and Clinic Appointments During Pandemics Such as COVID-19

Nikhil K Bommakanti et al. JAMA Ophthalmol. .

Abstract

Importance: During the coronavirus disease 2019 (COVID-19) pandemic, eye care professionals caring for patients with sight-threatening diseases, such as glaucoma, have had to determine whether some patient appointments could safely get postponed, weighing the risk that the patient's glaucoma could worsen during the interim vs the morbidity risk of acquiring COVID-19 while seeking ophthalmic care. They also need to prioritize appointment rescheduling during the ramp-up phase (when pandemic-associated service reductions are eased).

Objective: To describe a flexible and scalable scoring algorithm for patients with glaucoma that considers glaucoma severity and progression risk vs the presence of high-risk features for morbidity from COVID-19, using information from a large data repository.

Design, setting, and participants: In this cross-sectional study, patients with upcoming clinic appointments for glaucoma from March 16, 2020, to April 16, 2020, at an academic institution enrolled in the Sight Outcomes Research Collaborative (SOURCE) Ophthalmology Electronic Health Record Data Repository were identified. A risk stratification tool was developed that calculated a glaucoma severity and progression risk score and a COVID-19 morbidity risk score. These scores were summed to determine a total score for each patient.

Main outcomes and measures: Total scores and percentages of clinic appointments recommended for rescheduling.

Results: Among the 1034 patients with upcoming clinic appointments for glaucoma, the mean (SD) age was 66.7 (14.6) years. There were 575 women (55.6%), 733 White individuals (71%), and 160 Black individuals (15.5%). The mean (SD) glaucoma severity and progression risk score was 4.0 (14.4) points, the mean (SD) COVID-19 morbidity risk score was 27.2 (16.1) points, and the mean (SD) total score was 31.2 (21.4) points. During pandemic-associated reductions in services, using total score thresholds of 0, 25, and 50 points would identify 970 appointments (93.8%), 668 appointments (64.6%), and 275 appointments (26.6%), respectively, for postponement and rescheduling. The algorithm-generated total scores also helped prioritize appointment rescheduling during the ramp-up phase.

Conclusions and relevance: A tool that considers the risk of underlying ophthalmic disease progression from delayed care receipt and the morbidity risk from COVID-19 exposure was developed and implemented, facilitating the triage of upcoming ophthalmic appointments. Comparable approaches for other ophthalmic and nonophthalmic care during the COVID-19 pandemic and similar crises may be created using this methodology.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosure: Dr Ehrlich reported grants from National Institutes of Health during the conduct of the study. Dr Newman-Casey reported grants from National Eye Institute, Research to Prevent Blindness, and the Centers for Disease Control and Prevention during the conduct of the study. Dr Shah reported personal fees from Glaukos, Allergan, and Katena outside the submitted work. Dr Lee reported receiving grants from Research to Prevent Blindness; having received consulting fees from the Centers for Disease Control and Prevention; holding stocks in Pfizer, GSK, Merck, and Medco Health Solutions; and having received an honorarium from Alcon Research Institute outside the submitted work. Dr Stein reported grants from National Eye Institute during the conduct of the study. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Distribution of Risk Scores
Figure 2.
Figure 2.. Coronavirus Disease 2019 (COVID-19) Morbidity Risk Score vs Glaucoma Severity and Progression Risk Score
Dot sizes indicate the number of patients with a given combination of COVID-19 morbidity risk score and glaucoma severity/progression risk score. Shaded areas capture the patients whose appointments should get postponed and rescheduled based on different total score thresholds.
Figure 3.
Figure 3.. Number of Patient Appointments to Postpone Based on Different Total Score Thresholds
A and D, Distribution of patients at a threshold of 0. B and E, Distribution of patients at a threshold of 25. C and F, Distribution of patients at a threshold of 50.

References

    1. World Health Organization WHO Director-General’s opening remarks at the media briefing on COVID-19—11 March 2020. Published March 11, 2020. Accessed March 16, 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-re...
    1. Bialek S, Boundy E, Bowen V, et al. ; CDC COVID-19 Response Team . Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(12):343-346. doi:10.15585/mmwr.mm6912e2 - DOI - PMC - PubMed
    1. American Academy of Ophthalmology New recommendations for urgent and nonurgent patient care. Published March 18, 2020. Accessed March 20, 2020. https://www.aao.org/headline/new-recommendations-urgent-nonurgent-patien...
    1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242. doi:10.1001/jama.2020.2648 - DOI - PubMed
    1. Bai Y, Yao L, Wei T, et al. . Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020;323(14):1406-1407. doi:10.1001/jama.2020.2565 - DOI - PMC - PubMed

Publication types